A phase 1 dose escalation study of intra-articular administration of tgAAC94, a recombinant adeno-associated vector containing the TNFR:Fc [tumour necrosis factor alpha receptor immunoglobulin Fc fusion gene], in inflammatory arthritis

Trial Profile

A phase 1 dose escalation study of intra-articular administration of tgAAC94, a recombinant adeno-associated vector containing the TNFR:Fc [tumour necrosis factor alpha receptor immunoglobulin Fc fusion gene], in inflammatory arthritis

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2009

At a glance

  • Drugs TgAAC 94 (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2009 Results were published in the Annals of the Rheumatic Diseases.
    • 17 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top